U.S. Bioscience Inc. on Monday said it has granted Schering-Plough Corp. exclusive marketing rights to five anti-cancerdrugs in more than 35 countries in Latin America and the FarEast.
The agreement covers marketing rights to Hexalen, Ethyol, WR-151327, PALA and Rogletimide in Mexico, Brazil, Argentina,India, China and other countries. The United States, Europe,Japan, Korea and Thailand are excluded. Schering-Plough willpay royalties and other undisclosed payments, according toEllen Evans, manager of financial planning at U.S. Bioscience(AMEX: UBS).
Hexalen received FDA marketing approval in late 1989 fortreatment for ovarian cancer. U.S. sales of Hexalen were $3.4million in 1991, according to Evans. The FDA is currentlyreviewing Ethyol, a chemotherapy- and radiation-protectionagent. PALA, a drug that enhances the activity of certainchemotherapeutic agents, is in Phase III trials. The companyplans to file a new drug application for PALA in 1993,according to Evans. Rogletimide, a drug for the treatment ofbreast cancer, is in Phase II trials, while WR-151327, an oralversion of Ethyol, is in pre-clinical tests.
U.S. Bioscience shares on Monday closed up 50 cents at $16.38.-- Steve Usdin
(c) 1997 American Health Consultants. All rights reserved.